Clinical Trial Update: A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1/2 safety study evaluating CNTO 2476 in age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• CNTO 2476

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Age-related Macular Degeneration | Phase 1, Phase 2 | Status: COMPLETED